bs-0124R **[Primary Antibody]**

Calcitonin receptor Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 12311 **SWISS:** Q60755

Target: Calcitonin receptor

Immunogen: KLH conjugated synthetic peptide derived from mouse Calcitonin receptor: 31-120/516. < Extracellular >

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene encodes a high affinity receptor for the peptide hormone calcitonin and belongs to a subfamily of seven transmembrane-spanning G protein-coupled receptors. The encoded protein is involved in maintaining calcium homeostasis and in regulating osteoclast-mediated bone resorption. Polymorphisms in this gene have been associated with variations in bone mineral density and onset of osteoporosis. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Sep 2009]

Applications: **IHC-P** (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)

Reactivity: Rat (predicted: Mouse)

Predicted MW.: 53 kDa

Subcellular Location: Cell membrane

VALIDATION IMAGES



Paraformaldehyde-fixed, paraffin embedded (Rat testis); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CALCR) Polyclonal Antibody, Unconjugated (bs-0124R) at 1:500 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.

SELECTED CITATIONS

- **[IF=15.7]** Feng Kuanhan. et al. Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment. NAT COMMUN. 2025 May;16(1):1-16 FC ;Mouse. 40450037
- **[IF=15.1]** Linlin Tao. et al. Synergistic strategy based on mild phototherapy and deep tumor hypoxia reversal comprehensively remodels the tumor microenvironment for improved immunotherapy. CHEM ENG J. 2023 Sep;472:145092 IF ;Mouse. 10.1016/j.cej.2023.145092
- **[IF=14.903]** Tong Gao. et al. Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer. ACTA PHARM SIN B. 2022 Nov;: IF ;Mouse. 10.1016/j.apsb.2022.11.018
- **[IF=12.7]** Fangyu Qiao. et al. Growth factor collected cell membrane-functionalized matrix for vascular-innervated bone

regeneration. COMPOSITES PART B-ENGINEERING. 2025 Feb;291:112019 WB ;Rat. 10.1016/j.compositesb.2024.112019

- **[IF=13.116]** Yanmei He. et al. A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting. Sci Adv. 2021 Feb;7(6):eaba0776 IF ;Mouse. 33547067